Technical Analysis for ZLAB - Zai Lab Limited

Grade Last Price % Change Price Change
D 143.5 -3.05% -4.51
ZLAB closed down 8.65 percent on Tuesday, March 2, 2021, on 1.27 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical ZLAB trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish -3.05%
180 Bearish Setup Bearish Swing Setup -3.05%
Earnings Movers Other -3.05%
Multiple of Ten Bearish Other -3.05%
Inside Day Range Contraction -3.05%
Lower Bollinger Band Touch Weakness -3.05%
Oversold Stochastic Weakness -3.05%
Crossed Above 50 DMA Bullish -11.43%
Expansion Pivot Buy Setup Bullish Swing Setup -11.43%
Wide Range Bar Range Expansion -11.43%
Older End-of-Day Signals for ZLAB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% 10 minutes ago
Down 2 % 10 minutes ago
Down 1% 10 minutes ago
Fell Below Lower Bollinger Band 10 minutes ago
Bearish 180 Entry 10 minutes ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Infectious Diseases Natural Sciences Medication Chemical Substances Omadacycline

Is ZLAB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 193.54
52 Week Low 43.06
Average Volume 341,863
200-Day Moving Average 103.08
50-Day Moving Average 158.22
20-Day Moving Average 170.48
10-Day Moving Average 161.39
Average True Range 9.59
ADX 24.16
+DI 21.63
-DI 25.10
Chandelier Exit (Long, 3 ATRs ) 158.69
Chandelier Exit (Short, 3 ATRs ) 173.14
Upper Bollinger Band 194.61
Lower Bollinger Band 146.36
Percent B (%b) 0.03
BandWidth 28.31
MACD Line -2.31
MACD Signal Line 1.88
MACD Histogram -4.183
Fundamentals Value
Market Cap 13.03 Billion
Num Shares 88 Million
EPS -3.12
Price-to-Earnings (P/E) Ratio -47.50
Price-to-Sales 268.12
Price-to-Book 20.60
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 172.39
Resistance 3 (R3) 174.13 167.74 168.33
Resistance 2 (R2) 167.74 161.53 166.87 166.97
Resistance 1 (R1) 157.87 157.69 154.68 156.14 165.62
Pivot Point 151.48 151.48 149.88 150.61 151.48
Support 1 (S1) 141.62 145.27 138.42 139.88 130.40
Support 2 (S2) 135.23 141.44 134.36 129.05
Support 3 (S3) 125.36 135.23 127.69
Support 4 (S4) 123.63